| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenue | $32K | — | — | — |
| Cost of revenue | $424K | — | — | — |
| Sales, general and administrative compensation (inclusive of stock-based compensation) | $873K+21.6% | $718K+127.9% | $315K-3.1% | $325K |
| Sales and marketing | $24K-96.2% | $633K+873.8% | $65K | — |
| Professional Fees | $1.0M+125.3% | $446K-38.4% | $724K+0.3% | $722K |
| Research and development | $340K+22.3% | $278K-83.5% | $1.7M+37.4% | $1.2M |
| Depreciation and Amortization | $1.1M+2.3% | $1.1M-0.1% | $1.1M+0.6% | $1.1M |
| Rent and utilities | $74K+131.3% | $32K | — | — |
| Impairment of goodwill | $25.1M | — | — | — |
| Impairment of fixed assets | $263K | — | — | — |
| Loss on disposal of fixed assets | $12K | — | — | — |
| Other operating expenses | $417K+143.9% | $171K+43.7% | $119K | — |
| Total costs and expenses | $4.3M-85.0% | $28.8M+613.8% | $4.0M+16.6% | $3.5M |
| Operating loss | -$4.3M+85.1% | -$28.8M-613.8% | -$4.0M-18.3% | -$3.4M |
| Interest income | $13K+0.0% | $13K+0.0% | $13K-45.8% | $24K |
| Change in fair value of note payable, related party | -$9.4M-285.2% | $5.1M | — | — |
| Interest expense | -$793K+25.5% | -$1.1M-139.9% | -$444K+3.9% | -$462K |
| Loss from operations before income taxes | -$14.4M+41.6% | -$24.7M-461.3% | -$4.4M+44.0% | -$7.9M |
| Income tax benefit (expense) | $2.6M+7918.2% | -$33K | — | — |
| Net loss | -$11.9M+52.1% | -$24.8M-462.1% | -$4.4M+39.3% | -$7.3M |
| Loss from operations attributed to noncontrolling interest | $32K-48.4% | $62K-12.7% | $71K-65.2% | $204K |
| Net loss attributable to common stockholders | -$11.8M+52.1% | -$24.7M-469.8% | -$4.3M+38.5% | -$7.1M |
| Basic | $31.6M+193.3% | $10.8M-82.1% | $60.2M-14.5% | $70.5M |
| Diluted | $31.6M+193.3% | $10.8M-82.1% | $60.2M-14.5% | $70.5M |
| Biotech Retail Sales [Member] | ||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.